Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens

Anticancer Research

Volumn 28, Issue 6 B, 2008, Pages 3855-3858

  Igawa, Satoshi ^a   Takahashi, Toshiaki ^a   Nakamura, Yukiko ^a   Tsuya, Asuka ^a   Ono, Akira ^a   Shukuya, Takehiro ^a   Murakami, Haruyasu ^a   Endo, Masahiro ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Amrubicin; Chemotherapy failure; NSCLC; Third line treatment

Indexed keywords

AMRUBICIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM;

ADULT; AGED; ANAMNESIS; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 58149167039     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Schiller JH, Harrington D, Belani CP et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
2. Ohe Y, Ohashi Y, Kubota K et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007.
3. Shepherd FA, Dancey J, Ramlau R et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-3013, 2000.
4. Roszkowski K, Pluzanska A, Krzakowski M et al: A multicenter, randomized phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or nonresectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27: 145-157, 2000.
5. Shepherd FA, Rodrigues Pereira J et al: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005.
6. Douillard J-Y, Kim ES, Hirsh V et al: Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA™) versus intravenous docetaxel in patients with locally advanced or metastatic non-small cell lung cancer who have previously received platinum-based chemotherapy (INTEREST). Eur J Cancer 5: 2007 (suppl.).
7. Thatcher N, Chang A, Parikh P et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa™ Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005.
8. Ando M, Okamoto I, Yamamoto N et al: Predictive factors for interstitial lung disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 24: 2549-56, 2006.
9. Sawa T, Yana T, Takada M et al: Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial. Invest New Drugs 24: 151-158, 2006.
10. Takeda K, Takifuji N, Negoro S et al: Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 25: 377-383, 2007.
11. Onoda S, Masuda N, Seto T et al: Phase II trial of amrubicin for treatment of refractory or relapsed small cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 24: 5448-53, 2006.
12. Igawa S, Yamamoto N, Ueda S et al: Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol 2: 741-4, 2007.
13. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0, DCTD, NCI, NIH, DHHS. August 9, 2006.
14. Massarelli E, Andre F, Liu DD et al: A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small cell lung cancer. Lung Cancer 39: 55-61, 2003.